At-Risk for Type 1 Diabetes Extension Study

At-Risk for Type 1 Diabetes Extension Study
Condition:   Diabetes Mellitus, Type 1
Intervention:   Biological: teplizumab
Sponsor:   Provention Bio, Inc.

Source: View full study details on

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 29, 2022Comments | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine